Lee S. Schwartzberg MD, FACP
Medical Director, West Cancer Center, Memphis, Tennessee; Chief Medical Officer, OneOncologyLee S. Schwartzberg, MD, FACP, is professor of medicine at The University of Tennessee Health Science Center in Memphis, Chief Medical Officer at OneOncology, and medical director of the West Cancer Center, as well as a practicing medical oncologist.
Upon earning his MD degree from the New York Medical College in Valhalla, NY, Dr Schwartzberg completed an internship and a residency in internal medicine at the Cornell University North Shore University Hospital in Manhasset, NY. He then served as chief resident at Memorial Sloan Kettering Cancer Center in New York City and completed a fellowship in medical oncology/hematology.
The author or coauthor of more than 250 publications on medical oncology, hematology, and biosimilars, Dr Schwartzberg has been a leader in and educating healthcare professionals about the potential benefits of biosimilars in oncology practice. He has been very active in the work of the National Comprehensive Cancer Network, having served on its Board of Directors, the Guideline Steering Committee, and the Breast Cancer Guideline Panel, among others. He is past founding chairman of the Association of Community Cancer Centers Immuno-Oncology Institute and the editor-in-chief of the website PracticeUpdate Oncology.
Positions:
Medical Director, West Cancer Center, Memphis, Tennessee
Chief Medical Officer, OneOncology
Degrees:
State University of New York, BA and MS
New York Medical College, MD, FACP
Postgraduate Training:
Intern, North Shore University Hospital, Manhasset, NY
Fellow in medical oncology/hematology, Memorial Sloan-Kettering Cancer Center
Board Certifications:
Medical oncology
Hematology
Clinical Interests:
Medical oncology/hematology
Disclosures
He is a consultant for Amgen, Pfizer, Helsinn, Genentech, BMS, Myriad, AstraZeneca, Spectrum, and Napo.
He is also on the advisory board for Genomic Health Research Funding (Institution): Amgen and DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Standard Anthracycline-Based vs Docetaxel–Capecitabine in Early High–Clinical and/or –Genomic Risk Breast Cancer
- Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer
- Biosimilars for HER2-Targeted Antibodies
- High-Dose Chemotherapy With HSCT for High-Risk Breast Cancer and Four or More Involved Axillary Lymph Nodes
- Endocrine Therapy ± Whole Breast Irradiation in Low-Risk Breast Cancer Patients After Breast-Conserving Surgery
- Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-Trastuzumab Emtansine
- Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer
- Essential Presentations at SABCS 2019
- Tesetaxel Plus Capecitabine for Patients With Metastatic Breast Cancer
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer